CN110974865A - Composition for preventing or treating climacteric symptoms comprising fermented extract of pueraria lobata - Google Patents
Composition for preventing or treating climacteric symptoms comprising fermented extract of pueraria lobata Download PDFInfo
- Publication number
- CN110974865A CN110974865A CN201910931139.0A CN201910931139A CN110974865A CN 110974865 A CN110974865 A CN 110974865A CN 201910931139 A CN201910931139 A CN 201910931139A CN 110974865 A CN110974865 A CN 110974865A
- Authority
- CN
- China
- Prior art keywords
- saccharomyces
- extract
- fermented
- pueraria
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 96
- 206010027304 Menopausal symptoms Diseases 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 235000010575 Pueraria lobata Nutrition 0.000 title claims description 35
- 241000219781 Pueraria montana var. lobata Species 0.000 title 1
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 claims abstract description 68
- 241000219780 Pueraria Species 0.000 claims abstract description 49
- 241000235070 Saccharomyces Species 0.000 claims abstract description 43
- 235000013305 food Nutrition 0.000 claims abstract description 36
- 238000000855 fermentation Methods 0.000 claims abstract description 34
- 230000004151 fermentation Effects 0.000 claims abstract description 34
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 claims abstract description 34
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 claims abstract description 34
- MCYJIRFKDCXYCX-YUPZTAPUSA-N COc1c(O[C@@H]2O[C@H](CO[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O Chemical compound COc1c(O[C@@H]2O[C@H](CO[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O MCYJIRFKDCXYCX-YUPZTAPUSA-N 0.000 claims abstract description 21
- MCYJIRFKDCXYCX-UHFFFAOYSA-N tectorigenin 7-O-xylosylglucoside Natural products COc1c(OC2OC(COC3OCC(O)C(O)C3O)C(O)C(O)C2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O MCYJIRFKDCXYCX-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- FHFSSMDJUNVMNY-UHFFFAOYSA-N tectoridin Natural products COc1c(O)c2C(=O)C(=COc2cc1OC3OC(CO)C(O)C(O)C3O)c4cccc(O)c4 FHFSSMDJUNVMNY-UHFFFAOYSA-N 0.000 claims abstract description 16
- CNOURESJATUGPN-UDEBZQQRSA-N tectoridin Chemical compound C1=C2OC=C(C=3C=CC(O)=CC=3)C(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNOURESJATUGPN-UDEBZQQRSA-N 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 15
- 206010016825 Flushing Diseases 0.000 claims abstract description 11
- 241000628997 Flos Species 0.000 claims abstract description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 35
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 35
- 244000046146 Pueraria lobata Species 0.000 claims description 34
- 238000002360 preparation method Methods 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 244000253911 Saccharomyces fragilis Species 0.000 claims description 11
- 235000018368 Saccharomyces fragilis Nutrition 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 208000006820 Arthralgia Diseases 0.000 claims description 7
- 206010003694 Atrophy Diseases 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 206010029216 Nervousness Diseases 0.000 claims description 7
- 230000037444 atrophy Effects 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 230000035900 sweating Effects 0.000 claims description 7
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 206010046914 Vaginal infection Diseases 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 201000008100 Vaginitis Diseases 0.000 claims description 4
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 201000003146 cystitis Diseases 0.000 claims description 4
- 206010013990 dysuria Diseases 0.000 claims description 4
- 206010017062 Formication Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 206010027566 Micturition urgency Diseases 0.000 claims description 3
- 206010033557 Palpitations Diseases 0.000 claims description 3
- 208000012886 Vertigo Diseases 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 206010016256 fatigue Diseases 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 208000013465 muscle pain Diseases 0.000 claims description 3
- 208000035824 paresthesia Diseases 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 210000001635 urinary tract Anatomy 0.000 claims description 3
- 231100000889 vertigo Toxicity 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims 4
- 206010027175 memory impairment Diseases 0.000 claims 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 abstract description 12
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 abstract description 12
- 238000006243 chemical reaction Methods 0.000 abstract description 12
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 abstract description 12
- 150000002338 glycosides Chemical group 0.000 abstract description 11
- 238000001727 in vivo Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 description 20
- 230000006872 improvement Effects 0.000 description 16
- 230000036541 health Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- -1 flavonoid compounds Chemical class 0.000 description 11
- 235000013376 functional food Nutrition 0.000 description 11
- 241000186660 Lactobacillus Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940039696 lactobacillus Drugs 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 239000003075 phytoestrogen Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010048218 Xeroderma Diseases 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229930012930 isoflavone derivative Natural products 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/42—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
- A23L13/42—Additives other than enzymes or microorganisms in meat products or meat meals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Abstract
A composition for preventing or treating climacteric symptoms comprises fermented extract of flos Puerariae Lobatae. The present invention relates to a food composition for preventing or improving climacteric symptoms comprising a pueraria flower (Pueraria flowers) fermented extract; a pharmaceutical composition; a pharmaceutical composition for external use; a method for preparing the pueraria flower fermentation extract; and a method for preventing or improving climacteric symptoms. The fermented pueraria flower extract of the present invention can be usefully applied to relieve and improve various climacteric symptoms such as facial flushing by improving in vivo availability through the conversion of Tectorigenin 7-O-xylosylglucoside (Tectorigenin 7-O-xylosylglucoside) and/or Tectorigenin (Tectoridin) in a glycoside form contained in pueraria flower into Tectorigenin (Tectorigenini) as an aglycone using a saccharomyces strain.
Description
Technical Field
The present invention relates to a food composition for preventing or improving climacteric symptoms comprising a pueraria flower (Pueraria flowers) fermented extract; a pharmaceutical composition; a pharmaceutical external product (Quasi-drug) composition; the preparation method of the flos Puerariae Lobatae fermented extract; and a method for preventing or improving climacteric symptoms.
Background
Up to about 1 year after menopause occurs, the transition phase of menopause, commonly called menopause, is typically an average of 4-7 years. According to the korean menopause society, about 89% of korean women over 50 years old have climacteric symptoms. Menopause shows disorders of glucose metabolism, lipid metabolism, bone homeostasis and energy metabolism, so menopausal women may develop climacteric symptoms such as flushing, sweating, atrophy of the genitourinary system (feeling of vaginal dryness, vaginitis due to recurrent vaginal infections and urinary system infections, cystitis, dysuria, urgency), mental instability (concentration disorders as well as short-term memory disorders, anxiety and nervousness, memory decline), changes in the skin joint system (dry and atrophic skin, muscle pain, joint pain), an increase in bone fracture due to the progression of osteoporosis and an increase in Body Mass Index (BMI).
The administration of synthetic estrogen preparations is known to solve some of these climacteric symptoms, but on the other hand, it is a problem due to the side effects that increase the risk of breast cancer or endometrial cancer. Therefore, recently, attention has been increasingly focused on phytoestrogens (phytoestrogens) of natural estrogens of plants that are similar in structure and function to estrogens (e.g., isoflavones, flavonoids, lignans, etc.). In addition, with the increasing reports of the use of natural compounds such as the above-mentioned flavonoids as selective estrogen receptor modulators, studies on natural herbs as candidate substances for preventing, improving and treating climacteric disorders have been actively conducted, and thus red ginseng complex compositions having an effect on improving female climacteric disorders have been developed (korean laid-open patent No. 10-2006-0061323) and the like. However, the reality is that its efficacy is still uncertain.
On the other hand, flavonoid compounds derived from natural products (e.g., phytoestrogens, which are phytoestrogens) exist in nature in a glycoside form, and these glycosides must be converted into a aglycon form by intestinal microorganisms before they can be absorbed into the intestine and utilized. However, since the above-mentioned components are generally difficult to convert into aglycones after being ingested in glycoside forms due to differences among individuals, health conditions, abnormalities in intestinal flora, and the like, there are many limitations in their utilization. Therefore, research into biotransformation of active ingredients in the form of these glycosides into absorbable forms and development of products have been actively conducted, and the demand therefor is also on the rise.
Under such circumstances, the present inventors have made an effort to develop a composition having an effect of improving the in vivo availability of active ingredients derived from natural products and relieving and improving climacteric symptoms, and have confirmed that the prevention and improvement effects of climacteric symptoms are further increased when a pueraria flower extract is fermented using a strain of yeast (Saccharomyces), thereby completing the present invention.
Disclosure of Invention
Technical subject
An object of the present invention is to provide a food composition for preventing or improving climacteric symptoms, which comprises a pueraria flower (Pueraria flowers) fermented extract.
Another object of the present invention is to provide a pharmaceutical composition for preventing or treating climacteric symptoms, which comprises a fermented extract of pueraria lobata.
It is still another object of the present invention to provide a pharmaceutical composition for preventing or improving climacteric symptoms, which comprises a fermented extract of pueraria lobata.
It is still another object of the present invention to provide a pharmaceutical composition for external use for preventing or improving climacteric symptoms, which comprises a fermented extract of pueraria lobata.
Still another object of the present invention is to provide a method for preparing a pueraria flower fermented extract, comprising: (a) a step of inoculating a saccharomyces strain to a pueraria flower extract extracted with an extraction solvent; and (b) fermenting the pueraria lobata flower extract inoculated with the strain at 20 to 40 ℃ for 24 to 100 hours.
Means for solving the problems
The concrete description is as follows. On the other hand, the respective descriptions and embodiments disclosed in the present application can also be applied to the respective different descriptions and embodiments. That is, all combinations of the various elements disclosed in the present application are within the scope of the present application. In addition, the scope of the present application is not limited by the following detailed description.
An aspect of the present invention for achieving the above objects provides a food composition for preventing or improving climacteric symptoms, which comprises a pueraria flower (pueraiae flowers) fermented extract.
The invention is based on the following technical ideas: when the pueraria lobata extract is fermented using a saccharomyces strain, Tectorigenin 7-O-xylosylglucoside (tecorigenin 7-O-xylosylglucoside) and/or Tectoridin (tecoridin) in a glycoside form contained in pueraria lobata is converted into Tectorigenin (tecorigenin) as an aglycone, thereby improving in vivo availability, and thus the effect of preventing and improving climacteric symptoms is further increased, which was first elucidated by the present inventors. In particular, it was confirmed that when a pueraria flower extract was fermented using Saccharomyces cerevisiae (Saccharomyces cerevisiae), tectorigenin 7-O-xylosyl glucoside and tectoridin were both converted into tectorigenin, and tectorigenin was obtained in high yield. That is, when the pueraria lobata flower extract is fermented with the above-mentioned saccharomyces cerevisiae, the content of aglycone relative to glycoside in the pueraria lobata flower extract may be significantly increased, but is not limited thereto.
In the present invention, "Pueraria flower (pueraiae flowers)" is a flower of Pueraria lobata (pueraia thomosini) which is an perennial vine herb belonging to the family Leguminosae (Leguminosae), also called Pueraria flower, and is known as one of korean medicinal materials widely used in korean medicine. The pueraria flower may be a flower bud which does not flower, and commercially sold pueraria flower may be purchased, or pueraria flower which is picked or cultivated in nature may be used without limitation.
In the present invention, "fermentation" means decomposition of an organic substance by an enzyme possessed by a microorganism. In the present invention, the extract of pueraria lobata can be fermented by an edible microorganism strain, specifically, the microorganism may be a strain of Saccharomyces (Saccharomyces), more specifically, one or more strains selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces lactis, and Saccharomyces fragilis, and more specifically, Saccharomyces cerevisiae.
In the present invention, the "extract" refers to a product such as a solid component obtained by immersing a target substance in various solvents, extracting the resultant liquid component at room temperature, low temperature or heated state for a certain period of time, and removing the solvent from the liquid component. Moreover, the term "dilution" as used herein is intended to include all of the above-mentioned products, concentrates thereof, dried products obtained by drying the extract, and partially purified and purified products thereof.
The above extract can be extracted from natural, hybrid, and variety plants without limitation, and can be obtained by extracting with water (purified water), alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. In addition, the method for obtaining the above extract is not particularly limited as long as it can obtain a precipitated pueraria flower extract, and specifically, there can be used, for example, a cold immersion extraction method in which the above pueraria flower, dried pueraria flower, processed product, or the like is immersed in the above solvent and extracted at room temperature, a heating extraction method, an ultrasonic extraction method in which ultrasonic waves are applied for extraction, a reflux extraction method using a reflux condenser, or the like.
In the present invention, the "fermented extract" includes not only a useful substance itself produced by fermenting the above extract, but also a fermentation strain medium in which a fermentation strain and a fermentation product coexist, a fermentation product obtained by removing a fermentation strain by centrifugation from the above medium, a fermentation product obtained by filtering a fermentation strain from the above medium, a fermentation product obtained by sterilizing a fermentation strain from the above medium and filtering the fermentation strain, a dilution solution for diluting the above fermentation product, a dried product obtained by drying the above fermentation product, and the like.
In the present invention, the fermented extract may be a fermented extract of pueraria lobata obtained by fermenting an extract of pueraria lobata (Pueraria flowers). Specifically, the fermented extract of pueraria lobata may be fermented by a strain belonging to the genus Saccharomyces (Saccharomyces), more specifically, one or more strains selected from the group consisting of Saccharomyces cerevisiae (Saccharomyces cerevisiae), Saccharomyces lactis (Saccharomyces lactis), and Saccharomyces fragilis (Saccharomyces fragilis), more specifically, Saccharomyces cerevisiae. The pueraria flower fermentation extract of the invention converts glucoside in the extract into aglycone with high yield according to the characteristics of saccharomyces strain of fermentation microorganism, and obviously increases the content ratio of aglycone to glucoside, thereby improving the absorption capacity and utilization in organisms.
The pueraria lobata fermented extract of the present invention can convert Tectorigenin 7-O-xylosylglucoside (tecorigenin 7-O-xylosylglucoside) and/or Tectoridin (tecoridin) into Tectorigenin (tecorigenin) as an aglycone through microbial fermentation, thereby further increasing the in vivo absorbability.
In the present invention, tectorigenin 7-O-xylosyl glucoside is one of flavonoid compounds, and the molecular formula is C27H30O15And a molecular weight of about 594.5. The structure of tectorigenin 7-O-xylosyl glucoside is represented by the following chemical formula (1).
[ chemical formula 1]
In the present invention, "tectoridin" is one of the isoflavone glycosides, of the formula C22H22O11The molecular weight is about 462. The structure of tectoridin is represented by the following formula (2).
[ chemical formula 2]
Tectorigenin is one of isoflavone derivatives, exists in aglycone form, and has molecular formula of C16H12O6The molecular weight is about 300. Tectorigenin has a structure represented by the following chemical formula (3).
[ chemical formula 3]
The tectorigenin 7-O-xylosyl glucoside, tectorigenin and tectorigenin are ingredients contained in pueraria flower or pueraria flower extract to exhibit activity, and are useful as natural estrogens derived from plants. However, while tectorigenin 7-O-xylosyl glucoside and tectorigenin other than tectorigenin exist in a glycoside form and are thus hardly absorbed in the body, the present invention converts it into tectorigenin as an aglycone by fermentation using a yeast strain, thereby improving in vivo availability and further increasing the effect of relieving and improving climacteric symptoms.
In one example of the present invention, when 16 strains in total, including saccharomyces strain, were used to ferment the pueraria flower extract and the tectorigenin conversion amount was evaluated separately, it was confirmed that the tectorigenin conversion rate was significantly higher when using saccharomyces strain than other strains, and in particular, it was confirmed that both tectorigenin 7-O-xylosyl glucoside and tectoridin were converted into tectorigenin only when using saccharomyces cerevisiae to ferment the pueraria flower extract.
In the present invention, "menopausal symptoms" refer to symptoms and diseases that appear in women before and after menopause due to decreased estrogen secretion caused by aging of ovaries and the like. Also known as climacteric disorder, climacteric syndrome or menopausal symptoms. In the present invention, the above climacteric symptoms may include, for example, facial flushing, sweating, nervousness, depression, vertigo, fatigue, arthralgia, myalgia, headache, palpitation, formication, sweating in sleep, sleep disorder, xeroderma, vaginal dryness, vaginal atrophy, lower urinary tract atrophy, vaginitis, cystitis, dysuria, urinary urgency, concentration disorder, memory disorder, anxiety, nervousness, hypomnesis, xeroderma, arthralgia, osteoporosis, etc., and specifically, facial flushing may be mentioned, but not limited thereto.
In one example of the present invention, as a result of evaluating the improvement rate of facial flushing before and after the intake of the pueraria flower fermented extract, it was confirmed that the case of using the fermented extract of lactobacillus strain showed no great difference from the control group before fermentation, whereas the experimental group fermented using saccharomyces strain showed significantly superior improvement rate of cooper index compared to the control group and the experimental group fermented using lactobacillus strain, and in particular, it was confirmed that the case of using saccharomyces cerevisiae showed the most superior effect.
In the present invention, "prevention" means all of the actions of suppressing or delaying climacteric symptoms by ingesting or administering the composition of the present invention.
In the present invention, "improvement" means all of the behavior of improving or favorably changing climacteric symptoms as compared with the symptoms before administration by taking or administering the composition of the present invention.
In the present invention, "treatment" means all actions of improving or eliminating climacteric symptoms or related diseases by ingestion or administration of the composition of the present invention.
In one embodiment of the present invention, as a result of evaluating the improvement rate of the cooper index when the pueraria flower fermented extract fermented with the saccharomyces strain and the lactobacillus strain is ingested, it was confirmed that the case of the fermented extract with the lactobacillus strain shows no great difference from the control group before fermentation, whereas the experimental group fermented with the saccharomyces strain shows a significantly excellent improvement rate of the cooper index, particularly, the case of the saccharomyces cerevisiae shows the most excellent effect, compared to the control group and the experimental group fermented with the lactobacillus strain.
In the present invention, the "food" includes, for example, various foods, beverages, chewing gums, teas, vitamin compounds, health functional foods, and the like, and includes all foods in a general sense. The food can be prepared into dosage forms such as tablet, granule, powder, capsule, liquid solution and pill according to known preparation method, and the content of the fermented extract of the present invention can be adjusted to 0.0001-100 wt% based on the total weight of the food composition according to the dosage form. The food composition of the present invention is not particularly limited to other ingredients, in addition to containing the pueraria lobata fermented extract or a compound derived therefrom as an effective ingredient, and may contain conventional various flavors or natural carbohydrates, etc. as additional ingredients, and may further contain food auxiliary additives that are allowable in terms of food science.
In the present invention, the "food auxiliary additive" refers to a component that can be added to a food in an auxiliary manner, and is added when preparing a functional health food in various forms, and can be appropriately selected and used by those skilled in the art. Examples of the food auxiliary additive include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salt, alginic acid and its salt, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like, but the kind of the food auxiliary additive of the present invention is not limited to the above examples.
Health functional (sexual) foods may be included in the food composition of the present invention. The term "health functional food" as used herein means a food which is processed to have a high medical and medical effect of effectively exhibiting a bioregulatory function in addition to supplying nutrients, as a term similar to a food for special health use (FoSHU). The term "functional" refers to an effect useful for regulating nutrients in the structure and function of the human body or for health care such as physiological action. The health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and ingredients commonly added in the art when preparing the above health functional food. The formulation of the health functional food may be prepared without limitation as long as it is considered as a food formulation. The health functional food composition of the present invention can be prepared in various forms of dosage forms, and unlike general medicines, since food is used as a raw material, there are no side effects and the like that may occur by taking medicines for a long time, and it has an advantage of excellent portability.
The health functional food of the present invention may take a form without limitation, and may include all foods in a conventional sense, and may be used in combination with terms known in the art, such as functional foods. Also, the health functional food of the present invention may be prepared by mixing suitable other auxiliary ingredients and well-known additives, which may be included in the food, according to the selection of those skilled in the art. Examples of foods that can be added are meat, sausage, bread, chocolate, candies, snacks, cookies, pizza, instant noodles, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, oral liquids, alcoholic beverages, vitamin compounds, and the like, and can be prepared by adding to juice, tea, jelly, fruit juice, and the like prepared using the fermented extract of pueraria lobata according to the present invention as a main ingredient. In addition, food products for use as animal feed are also included.
In addition, the above-mentioned health functional food composition may further include a physiologically allowable carrier, the kind of which is not particularly limited and any carrier may be used as long as it is a carrier commonly used in the art. In addition, the above-mentioned health functional food composition may include additional ingredients that may be commonly used in food compositions to enhance smell, taste, vision, etc. without limitation, and may be selected according to the kind of food and used in an appropriate amount.
Another aspect of the present invention for achieving the above objects provides a pharmaceutical composition for preventing or treating climacteric symptoms, which comprises a fermented extract of pueraria flower. The flos Puerariae Lobatae, extract, fermented extract, climacteric symptom, and prevention and treatment are as described above.
In the present invention, the pharmaceutical composition may be used as a single preparation, or may further contain a drug known to have an effect of alleviating and improving climacteric symptoms and be prepared as a combined preparation, formulated with a pharmaceutically acceptable carrier or excipient so as to be prepared in a unit dosage form or packed in a large-volume container.
The pharmaceutical composition can be administered in a pharmaceutically effective amount. The above-mentioned "pharmaceutically effective amount" means an amount sufficient for preventing climacteric symptoms or treating related diseases at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level may be determined by the kind and severity of the individual, age, sex, activity of the drug, sensitivity to the drug, administration time, administration route and excretion ratio, treatment period, factors including the drug to be used simultaneously, and other factors well known in the medical field.
In accordance with still another aspect of the present invention for achieving the above objects, there is provided a pharmaceutical external composition for preventing or improving climacteric symptoms, comprising a fermented extract of pueraria lobata. The flos Puerariae Lobatae, extract, fermented extract, climacteric symptom, and prevention and treatment are as described above.
In the present invention, the pharmaceutical composition for external use may further include a pharmaceutically acceptable carrier, excipient or diluent, as necessary, in addition to the above-mentioned fermented extract of pueraria lobata. The above pharmaceutically allowable carrier, excipient or diluent is not limited as long as it does not impair the effects of the present invention, and for example, a filler, a bulking agent, a binder, a wetting agent, a disintegrant, a surfactant, a lubricant, a sweetener, an aromatic, a preservative, and the like may be contained.
The above-mentioned "pharmaceutically acceptable carrier" may refer to a carrier, excipient or diluent which does not irritate an organism while not deteriorating biological activity and characteristics of an injected compound, and specifically, may be a non-naturally occurring carrier. The kind of the carrier usable in the present invention is not particularly limited, and any carrier may be used as long as it is a pharmaceutically acceptable carrier commonly used in the art. Non-limiting examples of the above-mentioned carrier include physiological saline, sterilized water, ringer's solution, buffered physiological saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone, or 2 or more kinds may be mixed and used.
The above composition comprising a pharmaceutically acceptable carrier may be in various dosage forms for oral or non-oral administration. When formulated, the composition is prepared by using a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant and the like which are generally used. Specifically, solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and these solid preparations can be prepared by mixing the above-mentioned compounds with at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin and the like. Furthermore, lubricants such as magnesium stearate, talc may be used in addition to simple excipients. Liquid preparations for oral administration include suspensions, solutions for contents, emulsions, syrups and the like, and may contain various excipients such as wetting agents, sweeteners, aromatics, preservatives and the like in addition to water and liquid paraffin, which are commonly used simple diluents. Formulations for non-oral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations and suppositories. As non-aqueous solvents, suspending agents, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like may be used. As a base for suppositories, vinylogous (witepsol), polyethylene glycol, tween 61, cacao butter, lauric acid glyceride, glycerogelatin and the like can be used.
The pharmaceutical composition for external use according to the present invention may be exemplified by disinfectant detergents, shower foams, ointment liquids, wet tissues, paints, and the like, but is not limited thereto, and the method of preparation, amount, method of use, constituent components, and the like of the pharmaceutical composition for external use may be appropriately selected from conventional techniques known in the art.
Another aspect of the present invention for achieving the above objects provides a method for preparing a fermented pueraria flower extract, comprising: (a) a step of extracting the pueraria flower with an extraction solvent to prepare a pueraria flower extract; (b) inoculating a strain of Saccharomyces to the extract; and (c) culturing the strain inoculated in the above extract at 20 to 40 ℃ for 24 to 100 hours. The flos Puerariae Lobatae, extract, and fermented extract are as described above.
The Saccharomyces strain may be one or more selected from the group consisting of Saccharomyces cerevisiae (Saccharomyces cerevisiae), Saccharomyces lactis (Saccharomyces lactis), and Saccharomyces fragilis (Saccharomyces fragilis), and more specifically, may be Saccharomyces cerevisiae, but is not limited thereto. It will be apparent to those skilled in the art that inoculation and cultivation of the above strains can be carried out using methods and tools well known in the art. In the above-mentioned culturing step, the culturing temperature may be 20 to 40 ℃, more specifically, 25 ℃ and the culturing time may be 24 to 100 hours, but is not limited thereto.
When the fermented pueraria flower extract is prepared according to the preparation method of the present invention, tectorigenin 7-O-xylosyl glucoside and/or tectoridin in a glycoside form may be converted into tectorigenin as an aglycon by a fermentation process of a saccharomyces strain to improve in vivo utilization, thereby being usefully applied to the preparation of a composition for relieving, improving or treating various climacteric symptoms.
Still another aspect of the present invention for achieving the above objects provides a method for preventing or improving climacteric symptoms, comprising the step of administering a composition comprising a fermented extract of pueraria lobata to an individual other than human. The flos Puerariae Lobatae, extract, fermented extract, climacteric symptom, and the prevention and improvement are described above.
In the present invention, "administration" means introducing the composition of the present invention into an individual in any suitable manner, and the administration route of the above composition may be any general route as long as it can reach a target tissue to exhibit an effect of alleviating or improving climacteric symptoms or the like. The administration may be, but is not limited to, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, and intranasal administration. The composition of the present invention is administered daily or intermittently, and the administration may be performed 1 time or 2 to 3 times per day. In addition, the composition of the present invention can be used alone or in combination with other drugs for the relief and improvement of climacteric symptoms. In view of all the above factors, it is important to invest an amount capable of achieving the maximum effect in the minimum amount without side effects, and this can be easily determined by those skilled in the art.
In the present invention, the term "subject" refers to any animal such as a monkey, cow, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rabbit or guinea pig including a person who has suffered from or is likely to suffer from the above-mentioned climacteric symptoms, and by administering the composition of the present invention to the subject, the climacteric symptoms or diseases related thereto can be effectively prevented, improved or treated.
Effects of the invention
The fermented pueraria flower extract of the present invention can be usefully applied to relieve and improve various climacteric symptoms such as facial flushing by improving in vivo availability through the conversion of Tectorigenin 7-O-xylosylglucoside (Tectorigenin 7-O-xylosylglucoside) and/or Tectorigenin (Tectoridin) in a glycoside form contained in pueraria flower into Tectorigenin (Tectorigenini) as an aglycone using a saccharomyces strain.
Detailed Description
Hereinafter, the present invention will be described in more detail by the following examples. However, these examples are merely for illustrating the present invention, and the scope of the present invention is not limited to only these examples.
Example 1: preparation method of flos Puerariae Lobatae (Pueraria flowers) fermented extract
About 10 times of alcohol was added to dried raw material of pueraria flower (Pueraria flowers), and extracted twice with 70% alcohol at 68-72 ℃. Filtering the extract, concentrating at 45-55 deg.C under 1 atm to 20-30 Brix, and adding appropriate amount of dextrin to make into powder. A total of 16 strains of yeast (Saccharomyces), Lactobacillus (Lactobacillus), Bacillus (Bacillus) and Streptococcus (Streptococcus) strains were inoculated into a liquid medium containing the above pueraria lobata extract in an amount of 1 to 10 wt%, and the pueraria lobata extract inoculated with the strains was cultured at 25 ℃ for 24 hours, thereby preparing pueraria lobata fermented extracts (experimental groups 1 to 15).
Example 2: confirming the conversion level of tectorigenin according to the species of the fermentation strain
In each of the fermented extracts of pueraria lobata prepared in the above example 1, the degree of conversion of Tectorigenin 7-O-xylosylglucoside (Tectorigenin 7-O-xylosylglucoside) and/or Tectorigenin (Tectoridin) in glycoside form into Tectorigenin (Tectorigenini) as an aglycone was evaluated according to the kind of strain. The group to which the pueraria flower extract (1%) that had not undergone the fermentation step was added in the MRS medium was set as a control group.
[ Table 1]
As a result, as can be seen from table 1 above, it was confirmed that experimental groups 1 to 3 using the saccharomyces strain showed significantly high conversion rates of tectorigenin as compared with other strains. In particular, in the case of experimental group 1 in which the pueraria lobata extract was fermented using saccharomyces cerevisiae, it was confirmed that both tectorigenin 7-O-xylosyl glucoside and tectoridin were converted into tectorigenin in high yield, and the obtained tectorigenin concentration was very high.
That is, this is a result showing: when the pueraria lobata extract is fermented with a saccharomyces strain, particularly saccharomyces cerevisiae, the glycoside-form active ingredient contained in the pueraria lobata extract is converted into an aglycone form, so that the concentration thereof is significantly increased, and thus the in vivo availability is increased, thereby exhibiting an excellent effect of preventing or improving climacteric symptoms.
Example 3: confirming the improvement rate of climacteric symptoms of the fermented extract of flos Puerariae Lobatae according to the type of the fermentation strain
In order to determine whether each of the fermented extracts of pueraria lobata prepared in example 1 above actually showed a relieving or improving effect of climacteric symptoms, the fermented extracts of the above experimental groups 1 to 5 were powdered and 5g was ingested each time for 4 weeks, and then the improving rate of climacteric symptoms and the improving rate of facial flushing, which is a typical climacteric symptom, were evaluated. The improvement rate of climacteric symptoms was calculated by the improvement rate of cooper's index before and after ingestion, and the results thereof are shown in table 2 below. The facial flushing score is displayed as the cumulative sum of the intensity x number of facial flushes felt during the day, on a scale of 4 points, giving a score of 1 for "mild symptoms", 2 for "moderate symptoms", 3 for "severe symptoms" and 4 for "very severe symptoms". The cooper index and the face flush improvement rate were calculated as follows.
Improvement rate (%) - (post-ingestion measure-pre-ingestion measure)/pre-ingestion measure 100
[ Table 2]
As can be seen from table 2 above, it was confirmed that the fermentation extracts of the experimental groups 4 and 5 using lactobacillus strains showed no significant difference compared to the control group before fermentation, and on the contrary, the experimental groups 1 to 3 using saccharomyces strains also showed significantly superior improvement rate of cooper index and improvement rate of surface flushing compared to the control group and the experimental group using lactobacillus strains for fermentation. In particular, in the case of test group 1 using saccharomyces cerevisiae, it was found that tectorigenin was excellent in conversion rate, and that the improved kupperman index and improved facial flushing rate were also the highest, and that the test group showed excellent effects on preventing or improving climacteric symptoms.
Example 4: evaluation of the level of conversion of tectorigenin according to the fermentation time of Saccharomyces cerevisiae
The conversion level of tectorigenin according to the fermentation time was evaluated for the fermentation extract using a strain of saccharomyces cerevisiae, which was confirmed to show the most excellent conversion rate of tectorigenin and improvement rate of cooper's index by the above examples 2 and 3. Specifically, changes in the concentration of tectorigenin 7-O-xylosyl glucoside, tectoridin and tectorigenin according to fermentation time (24 hours, 48 hours, 72 hours) were measured, and the results are shown in Table 3 below.
As a result, in the case of the pueraria lobata fermented extract prepared using the saccharomyces cerevisiae strain as an experimental group, it was confirmed that the level of conversion into tectorigenin was increased in proportion to the fermentation time, which was a result showing the following: the tectorigenin content as an aglycone is increased to a significant level compared to the pueraria lobata extract which has not been subjected to a fermentation process, thereby greatly improving in vivo utilization.
[ Table 3]
Based on the above description, it will be understood by those skilled in the art to which the present invention pertains that the present invention may be embodied in other specific forms without changing the technical spirit or essential features of the invention. In this regard, it should be understood that the above-described embodiments are illustrative in all respects and not restrictive. The scope of the present invention should be construed to include the meaning and scope of the appended claims and all changes or modifications derived from the concept equivalent thereto, and should not be construed to include only the above detailed description.
Claims (18)
1. A food composition for preventing or improving climacteric symptoms, which comprises a fermented extract of Pueraria flower (Pueraria flors) fermented with a strain of the genus Saccharomyces.
2. The food composition of claim 1, wherein the Saccharomyces strain is one or more strains selected from the group consisting of Saccharomyces cerevisiae (Saccharomyces cerevisiae), Saccharomyces lactis (Saccharomyces lactis), and Saccharomyces fragilis (Saccharomyces fragilis).
3. The food composition of claim 2, wherein the Saccharomyces strain is Saccharomyces cerevisiae (Saccharomyces cerevisiae).
4. The food composition of claim 1, wherein the fermented extract is prepared by extraction with a solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms, and a mixed solvent thereof.
5. Food composition according to claim 1, wherein the fermented extract is present in an amount of 1 to 10 wt.% (w/w) relative to the total weight of the composition.
6. The food composition of claim 1, wherein Tectorigenin 7-O-xylosylglucoside (Tectorigenin 7-O-xylosylglucoside) and/or Tectoridin (Tectoridin) in the fermented pueraria lobata extract is converted to Tectorigenin (Tectorigenini) such that the fermented extract has increased absorption capacity as compared to the pueraria lobata extract.
7. The food composition of claim 1, wherein the climacteric symptom is selected from the group consisting of facial flushing, sweating, nervousness, depression, vertigo, fatigue, joint pain, muscle pain, headache, palpitation, formication, sweating during sleep, sleep disorders, dry skin, vaginal dryness, vaginal atrophy, lower urinary tract atrophy, vaginitis, cystitis, dysuria, urinary urgency, concentration disorders, memory disorders, anxiety, nervousness, memory impairment, dry skin, joint pain, and osteoporosis.
8. The food composition according to claim 1, wherein the climacteric symptom is facial flushing.
9. A pharmaceutical composition for preventing or treating climacteric symptoms, which comprises a fermented extract of Pueraria flower (Pueraria flors) fermented with a strain of the genus Saccharomyces.
10. The pharmaceutical composition of claim 9, wherein the Saccharomyces strain is one or more strains selected from the group consisting of Saccharomyces cerevisiae (Saccharomyces cerevisiae), Saccharomyces lactis (Saccharomyces lactis), and Saccharomyces fragilis (Saccharomyces fragilis).
11. The pharmaceutical composition of claim 10, wherein the Saccharomyces strain is Saccharomyces cerevisiae (Saccharomyces cerevisiae).
12. The pharmaceutical composition of claim 9, wherein Tectorigenin 7-O-xylosylglucoside (Tectorigenin 7-O-xylosylglucoside) and/or Tectoridin (Tectoridin) in the fermented pueraria lobata extract is converted to Tectorigenin (Tectorigenini) such that the fermented extract has increased absorption capacity as compared to the pueraria lobata extract.
13. The pharmaceutical composition of claim 9, wherein the climacteric symptom is selected from the group consisting of facial flushing, sweating, nervousness, depression, vertigo, fatigue, joint pain, muscle pain, headache, palpitation, formication, sweating during sleep, sleep disorders, dry skin, vaginal dryness, vaginal atrophy, lower urinary tract atrophy, vaginitis, cystitis, dysuria, urinary urgency, concentration disorders, memory disorders, anxiety, nervousness, memory impairment, dry skin, joint pain, and osteoporosis.
14. A pharmaceutical external composition for preventing or improving climacteric symptoms, which comprises a fermented extract of flos Puerariae Lobatae (Pueraria floras) fermented with a strain of the genus Saccharomyces.
15. A preparation method of a pueraria flower fermentation extract comprises the following steps:
(a) a step of inoculating a saccharomyces strain to a pueraria flower extract extracted with an extraction solvent; and
(b) fermenting the pueraria flower extract inoculated with the strain at 20 to 40 ℃ for 24 to 100 hours.
16. The method according to claim 15, wherein the Saccharomyces strain is one or more strains selected from the group consisting of Saccharomyces cerevisiae (Saccharomyces cerevisiae), Saccharomyces lactis (Saccharomyces lactis), and Saccharomyces fragilis (Saccharomyces fragilis).
17. The method according to claim 16, wherein the Saccharomyces strain is Saccharomyces cerevisiae (Saccharomyces cerevisiae).
18. A method for preventing or improving climacteric symptoms comprises the step of administering a composition comprising a fermented extract of flos Puerariae Lobatae to an individual other than human.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0117816 | 2018-10-02 | ||
| KR1020180117816A KR102178967B1 (en) | 2018-10-02 | 2018-10-02 | A Composition for preventing or treating menopausal symptoms comprising fermented Puerariae flos extracts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110974865A true CN110974865A (en) | 2020-04-10 |
Family
ID=70081854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910931139.0A Pending CN110974865A (en) | 2018-10-02 | 2019-09-29 | Composition for preventing or treating climacteric symptoms comprising fermented extract of pueraria lobata |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102178967B1 (en) |
| CN (1) | CN110974865A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239092A (en) * | 2008-03-14 | 2008-08-13 | 山东省医学科学院药物研究所 | Kudzuvine flower isoflavonoid extraction, its extracting method, medicinal composition and its use in pharmaceutical |
| CN101518563A (en) * | 2008-02-27 | 2009-09-02 | 北京凯瑞创新医药科技有限公司 | Non-oral preparation of pachyrhizua angulatus total aglycon, preparation method and application thereof |
| CN107232607A (en) * | 2017-07-10 | 2017-10-10 | 深圳市华生美康生物科技有限公司 | A kind of plant fermented liquid and its zymotechnique with relieving alcoholism and protecting liver effect |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120125042A (en) * | 2011-05-06 | 2012-11-14 | 김영욱 | A process for preparing a fermented broth of herbal medicine by combined microorganisms, a fermented broth prepared by the process, and a fermented food prepared by the fermented broth |
| KR102204346B1 (en) * | 2016-04-25 | 2021-01-18 | 주식회사 엘지생활건강 | Composition for relieving menopausal symptom or osteoporosis |
| KR101965849B1 (en) * | 2017-03-07 | 2019-04-04 | 주식회사 엘지생활건강 | Composition for relieving menopausal symptom comprising Tectorigenin 7-O-xylosylglucoside |
| KR101964841B1 (en) * | 2017-03-07 | 2019-08-07 | 주식회사 엘지생활건강 | Composition for relieving menopausal symptom |
-
2018
- 2018-10-02 KR KR1020180117816A patent/KR102178967B1/en active IP Right Grant
-
2019
- 2019-09-29 CN CN201910931139.0A patent/CN110974865A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518563A (en) * | 2008-02-27 | 2009-09-02 | 北京凯瑞创新医药科技有限公司 | Non-oral preparation of pachyrhizua angulatus total aglycon, preparation method and application thereof |
| CN101239092A (en) * | 2008-03-14 | 2008-08-13 | 山东省医学科学院药物研究所 | Kudzuvine flower isoflavonoid extraction, its extracting method, medicinal composition and its use in pharmaceutical |
| CN107232607A (en) * | 2017-07-10 | 2017-10-10 | 深圳市华生美康生物科技有限公司 | A kind of plant fermented liquid and its zymotechnique with relieving alcoholism and protecting liver effect |
Non-Patent Citations (3)
| Title |
|---|
| 张国峰: "葛花药材化学品质评价法及抗氧化药理活性的研究", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑 2015年》 * |
| 张雯煜等: "异黄酮的微生物发酵和酶转化生产", 《广西轻工业》 * |
| 王金凤等: "鸢尾苷元在兔体内的药动学", 《中成药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200038113A (en) | 2020-04-10 |
| KR102178967B1 (en) | 2020-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101346504B1 (en) | Equol-containing fermentation product of soybean embryonic axis, and method for production thereof | |
| EP2995304B1 (en) | Germinated and fermented bean extract and cosmetic or food use of a germinated and fermented bean extract | |
| CN108348565A (en) | A kind of composition for preventing and treating muscle disease or improving muscle function containing Radix Platycodonis extract | |
| CN105358168B (en) | Composition having function of relieving premenstrual syndrome and dysmenorrhea | |
| CN113694115A (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
| CN108697685A (en) | Containing moracin, Phellinus copper G or the root bark of white mulberry, the prevention of muscle disease and treatment is used or muscular function improvement composition | |
| CN110278706B (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with strain of Aspergillus coronarius | |
| US20090269424A1 (en) | Peripheral blood flow-improving composition | |
| KR102153414B1 (en) | Composition for improving hair loss and promoting hair growth containing a fermented soybean | |
| US10967028B2 (en) | Composition for hair loss prevention or hair growth stimulation comprising Artemisia umbelliformis extract | |
| KR101709281B1 (en) | Composition for Prevention or Treatment of Osteoporosis Comprising Herbal Extract and Fermentation Product thereof with Lactic acid Bacteria | |
| KR101199961B1 (en) | Composition for Prevention or Treatment of Osteoporosis Comprising Bangpungtongseungsan and Fermentation Product Thereof with Lactic Acid Bacteria | |
| KR20170121532A (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR102137136B1 (en) | Composition comprising pumpkin hydrolysis extract, amorphophallus paeoniifolius hydrolysis extract, curcuma extract and cacao nibs extract | |
| KR102114133B1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
| KR100733335B1 (en) | Fermentation Product of Puerariae Radix Extract and Composition for Prevention or Treatment of Osteoporosis Comprising the Same | |
| KR102275055B1 (en) | Composition comprising scutellaria alpina extract | |
| CN112472733B (en) | A flos Puerariae Lobatae extract for promoting calcium oral absorption | |
| KR102465484B1 (en) | Pharmaceutical composition for the prevention or treatment of obesity or metabolic syndrome induced from obesity containing heat-killed enteroccocus faecalis as an active ingredient | |
| KR20160079269A (en) | Anti-inflammatory pharmaceutical composition and health functional food containing artemisia fermentation extract | |
| KR102239415B1 (en) | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain | |
| EP3127547B1 (en) | Composition comprising extract of alpine wormwood | |
| CN110974865A (en) | Composition for preventing or treating climacteric symptoms comprising fermented extract of pueraria lobata | |
| JP2012067082A (en) | Oral composition | |
| KR102167812B1 (en) | Fermented product of sorghum-adzuki bean mixture for intestinal health and improvement effect of bowel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |